{"brief_title": "Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy", "brief_summary": "The purpose of this study is to determine if implitapide, used in conjunction with other lipid-lowering therapies, is safe and effective when compared to placebo in lowering low-density lipoprotein cholesterol (LDL-C) in patients with heterozygous familial hypercholesterolemia (HeFH).", "condition": "Familial Hypercholesterolemia", "intervention_type": "Drug", "intervention_name": "Implitapide", "criteria": "Inclusion Criteria: In order to participate in this study, patients must meet all of the following inclusion criteria: - be between 18 and 70 years old with a diagnosis of HeFH; - be stable on and maintain concomitant therapy with hypolipidemic drugs or treatments; - have an appropriate calculated, fasting LDL-C levels and an appropriate triglyceride (TG) level; - be male or nonpregnant, nonlactating female; - give informed consent; and - meet body weight requirements. Exclusion Criteria: In order to participate in this study, patients must not meet any of the following exclusion criteria: - recent myocardial infarction, percutaneous transluminal coronary intervention, coronary artery bypass graft surgery, or cerebrovascular accident; - uncontrolled hypothyroidism or other uncontrolled endocrine disease; - known, clinically significant eye abnormalities (e.g., cataracts); - appropriate serum creatinine phosphokinase levels; - history of liver disease or liver enzyme levels above appropriate levels; - alkaline phosphatase above appropriate levels; - serum creatinine above appropriate levels; - liver cirrhosis and severe liver steatosis; - clinically significant infection, malignancy, or psychosis; - use of oral anticoagulants or digoxin, unless the dose has been stable for 4 weeks; - participation in any other investigational study, including device or observational studies, within 30 days; - lactating or have a positive serum pregnancy test; - current drug or alcohol abuse; or - unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the investigator", "gender": "All", "minimum_age": "18 Years", "maximum_age": "70 Years", "healthy_volunteers": "No", "id": "NCT00079859.xml"}